About Convergent Therapeutics
Convergent Therapeutics is a company based in United States founded in 2020 by Philip Kantoff. Convergent Therapeutics has raised $130 million across 2 funding rounds from investors including Orbimed, RA Capital and Novo Holdings. The company has 4 employees as of December 31, 2022. Convergent Therapeutics offers products and services including CONV01-α and Radioantibodies. Convergent Therapeutics operates in a competitive market with competitors including Radionetics, Hinova Pharmaceuticals, Nymox Pharmaceutical, Madison Vaccines and Nuage Therapeutics, among others.
- Headquarter United States
- Employees 4 as on 31 Dec, 2022
- Founders Philip Kantoff
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Convergent Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$130 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series A
Jul 31, 2024
-
Investors
Orbimed
& 2 more
-
Employee Count
4
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Convergent Therapeutics
Convergent Therapeutics offers a comprehensive portfolio of products and services, including CONV01-α and Radioantibodies.
Targeted therapy using alpha radioantibodies for prostate cancer treatment.
Antibodies with alpha-emitting payloads for precise cancer cell targeting.
People of Convergent Therapeutics
Unlock access to complete
Funding Insights of Convergent Therapeutics
Convergent Therapeutics has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Convergent Therapeutics
Convergent Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Locked | Locked | Locked |
Investor details for Convergent Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Convergent Therapeutics
Investment portfolio details for Convergent Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Convergent Therapeutics
Detailed financials for Convergent Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Convergent Therapeutics Comparisons
Peer comparison for Convergent Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Convergent Therapeutics
Convergent Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Radionetics, Hinova Pharmaceuticals, Nymox Pharmaceutical, Madison Vaccines and Nuage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Develops small molecule based drug for multiple disease treatment
|
|
| Locked | Locked | Locked |
Provides research and development of novel drugs and diagnostic products for the aging population
|
|
| Locked | Locked | Locked |
Immunotherapies for prostate cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Drugs are developed for intrinsically disordered protein targets.
|
Detailed competitors of Convergent Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Convergent Therapeutics
Complete news archive for Convergent Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Convergent Therapeutics
Convergent Therapeutics was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Convergent Therapeutics is headquartered in United States.
Philip Kantoff is the current CEO of Convergent Therapeutics. They have also founded this company.
Convergent Therapeutics is a funded company, having raised a total of $130M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Convergent Therapeutics is 4.
Convergent Therapeutics was founded in 2020 in the United States and operates within the biotechnology sector. Focus is placed on developing treatments for cancer through a proprietary approach involving dual-targeted radionuclide therapy. This method is applied to create CONV01-α, in which a monoclonal antibody is conjugated with actinium-225 to deliver radioisotopes specifically to prostate cancer cells.
Convergent Therapeutics's top competitors include Radionetics, Nuage Therapeutics and Emtora Biosciences.
Convergent Therapeutics offers CONV01-α and Radioantibodies.
Convergent Therapeutics has 3 investors. Key investors include Orbimed, RA Capital, and Novo Holdings.